A Study of Alectinib (RO5424802) in Participants With Non-Small Cell Lung Cancer Who Have Anaplastic Lymphoma Kinase (ALK) Mutation and Failed Crizotinib Treatment

Clinical trial NCT01801111 · COMPLETED

Trial details

NCT number

NCT01801111

Sponsor

Hoffmann-La Roche

Status

COMPLETED

Phase

Phase 1, Phase 2

Study type

INTERVENTIONAL

Start date

2013-06-20

Primary completion

2014-10-24

Enrollment

138

View on ClinicalTrials.gov